Onkologie. 2017:11(1):14-18 | DOI: 10.36290/xon.2017.004

The update on treatment surgical management of renal tumors

Petr Macek
Urologická klinika 1. LF UK a VFN v Praze

Surgery is a method of choice for the management of localized and locally-advanced renal tumors. In cT1a (up to 4 cm) tumors

nephron-sparing approach (= partial nephrectomy) is current recommended standard, provided it is technically feasible and there

are no contraindications. The amount of nephron-sparing surgeries increases over time also owing to new technologies such as 3D

imaging during surgery, robot-assisted surgery, better hemostatic instruments and greater experience, which all lead to shorter

or no warm ischemia during nephron-sparing surgery. However, there is no long-term functional benefit in elderly patients over

75 years of age. Nevertheless, if preservation of functional parenchyma is needed, thermal ablation methods (radiofrequency ablation

or cryoablation) or active surveillance are possible. In management of locally advanced renal tumors R0 surgery is intended

as adjuvant systemic treatment in not yet the standard. For selected patients with distant metastases surgery, metastasectomy,

is possible. However, only complete metastasectomy of all lesions brings better overall survival.

Keywords: renal tumor, surgical management, partial nephrectomy

Published: February 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Macek P. The update on treatment surgical management of renal tumors. Onkologie. 2017;11(1):14-18. doi: 10.36290/xon.2017.004.
Download citation

References

  1. Ljungberg B, Bensalah K, Bex A, et al. EAU guidelines on renal cell carcinoma: 2016 update. European Association of Urology, 2016.
  2. Dušek L, Mužík J, Kubásek M, et al. Epidemiologie zhoubných nádorů v České republice [online]. http://www.svod.cz. Verze 7.0 (2007).
  3. Frank I, Blute ML, Cheville JC, et al. Solid Renal Tumors: An Analysis of Pathological Features Related to Tumor Size. The Journal of Urology, 2003; 170(6): 2217-2220. Go to original source... Go to PubMed...
  4. Bekema HJ, Maclennan S, IMAMURA M, et al. Systematic review of adrenalectomy and lymph node dissection in locally advanced renal cell carcinoma. Eur Urol, 2013; 64(5): 799-810. Go to original source... Go to PubMed...
  5. Weight CJ, Kim SP, Lohse CM, et al. Routine adrenalectomy in patients with locally advanced renal cell cancer does not offer oncologic benefit and places a significant portion of patients at risk for an asynchronous metastasis in a solitary adrenal gland. Eur Urol, 2011; 60(3): 458-64. Go to original source... Go to PubMed...
  6. Blom JH, Van Poppel H, Marechal JM, et al. Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. Eur Urol, 2009; 55(1): 28-34. Go to original source... Go to PubMed...
  7. Gershman B, Thompson RH, Moreira DM, et al. Radical Nephrectomy With or Without Lymph Node Dissection for Nonmetastatic Renal Cell Carcinoma: A Propensity Score-based Analysis. Eur Urol, 2016, doi: 10.1016/j.eururo.2016.09.019. Go to original source... Go to PubMed...
  8. Abaza R, Shabsigh A, Castle E, et al. Multi-Institutional Experience with Robotic Nephrectomy with Inferior Vena Cava Tumor Thrombectomy. J Urol, 2016; 195(4) Pt 1: 865-71. Go to original source... Go to PubMed...
  9. Feuerstein MA, Kent M, Bernstein M, et al. Lymph node dissection during cytoreductive nephrectomy: a retrospective analysis. Int J Urol, 2014; 21(9): 874-879. Go to original source... Go to PubMed...
  10. Capitanio U, Suardi N, Matloobr, et al. Extent of lymph node dissection at nephrectomy affects cancer-specific survival and metastatic progression in specific sub-categories of patients with renal cell carcinoma (RCC). BJU Int, 2014; 114(2): 210-215. Go to original source... Go to PubMed...
  11. Karam JA, Devine CE, Urbauer DL, et al. Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma. Eur Urol, 2014; 66(5): 874-880. Go to original source... Go to PubMed...
  12. Haas NB, Manola J, Uzzo RG, et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet, 2016; 387(10032): 2008-2016. Go to original source... Go to PubMed...
  13. Bazzi WM, Sjoberg DD, Feuerstein MA, et al. Long-term survival rates after resection for locally advanced kidney cancer: Memorial Sloan Kettering Cancer Center 1989 to 2012 experience. J Urol, 2015; 193(6): 1911-1916. Go to original source... Go to PubMed...
  14. Joyce DD, Psutka SP, Groeschl RT, et al. Complications and Outcomes Associated With Surgical Management of Renal Cell Carcinoma Involving the Liver: A Matched Cohort Study. Urology, 2016, doi: 10.1016/j.urology.[2016-08-015]. Go to original source... Go to PubMed...
  15. Yuki H, Kamai T, Kubota K, et al. Axitinib for preoperative downstaging of renal cell carcinoma with sarcomatoid differentiation and direct invasion of the duodenum and inferior vena cava: a case report. Onco Targets Ther, 2014; 7: 289-295. Go to original source... Go to PubMed...
  16. Nayak JG, Patel P, Bjazevic J, et al. Clinical outcomes following laparoscopic management of pT3 renal masses: A large, multi-institutional cohort. Can Urol Assoc J, 2015; 9(11-12): 397-402. Go to original source... Go to PubMed...
  17. Laird A, Choy KC, Delaney H, et al. Matched pair analysis of laparoscopic versus open radical nephrectomy for the treatment of T3 renal cell carcinoma. World J Urol, 2015; 33(1): 25-32. Go to original source... Go to PubMed...
  18. Shao P, Li J, Qin C, et al. Laparoscopic Radical Nephrectomy and Inferior Vena Cava Thrombectomy in the Treatment of Renal Cell Carcinoma. Eur Urol, 2015; 68(1): 115-122. Go to original source... Go to PubMed...
  19. Bex A, Powles T, Karam JA. Role of targeted therapy in combination with surgery in renal cell carcinoma. Int J Urol, 2016; 23(1): 5-12. Go to original source... Go to PubMed...




Oncology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.